The 5-year analysis of Gujarat Themis Biosyn Ltd's performance infers:
We analysed the performance of Gujarat Themis Biosyn Ltd share prices over the last 10 years. Here is what we found out:
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.
The company has world-wide exports to satisfied customers, having customised facility for all products.
The companyâ€™s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process.
The companyâ€™s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.
Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became Indiaâ€™s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.
Business area of the company